CollPlant Biotechnologies (CLGN) Retained Earnings (2017 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Retained Earnings came in at -$124.8 million in Q4 2025, down 10.14% YoY from -$138.9 million in Q4 2024, and down 2.64% on a QoQ basis from -$121.6 million in Q3 2025.
CollPlant Biotechnologies (CLGN) Retained Earnings (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 9 years of Retained Earnings data on file, last reported at -$124.8 million in Q4 2025.
- Quarterly Retained Earnings fell 10.14% year-over-year to -$124.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$124.8 million (down 10.14% YoY) and the FY2025 annual result came in at -$124.8 million, down 10.14% from the prior year.
- Retained Earnings fell to -$124.8 million in Q4 2025, from -$121.6 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$62.9 million in Q1 2021 to a low of -$124.8 million in Q4 2025.
- A 5-year average of -$93.0 million and a median of -$92.1 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2021 — Retained Earnings increased 8.64% — and 2022, when it declined 23.61%.
- Tracing CLGN's Retained Earnings over 5 years: stood at -$72.8 million in 2021, then decreased by 23.25% to -$89.7 million in 2022, then declined by 7.82% to -$96.7 million in 2023, then decreased by 17.17% to -$113.4 million in 2024, then declined by 10.14% to -$124.8 million in 2025.
- The last three Retained Earnings figures came in at -$124.8 million (Q4 2025), -$121.6 million (Q3 2025), and -$118.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -124.84 Mn |
| Sep 30, 2025 | -121.63 Mn |
| Jun 30, 2025 | -118.15 Mn |
| Dec 31, 2024 | -113.35 Mn |
| Sep 30, 2024 | -109.47 Mn |
| Jun 30, 2024 | -105.15 Mn |
| Mar 31, 2024 | -100.94 Mn |
| Dec 31, 2023 | -96.74 Mn |
| Sep 30, 2023 | -92.05 Mn |
| Jun 30, 2023 | -87.68 Mn |
| Mar 31, 2023 | -93.44 Mn |
| Dec 31, 2022 | -89.72 Mn |
| Sep 30, 2022 | -85.32 Mn |
| Jun 30, 2022 | -80.94 Mn |
| Mar 31, 2022 | -76.66 Mn |
| Dec 31, 2021 | -72.80 Mn |
| Sep 30, 2021 | -69.03 Mn |
| Jun 30, 2021 | -65.95 Mn |
| Mar 31, 2021 | -62.91 Mn |
| Dec 31, 2020 | -73.03 Mn |